Loading…
Surrozen, Inc.
Surrozen, Inc. (SRZN) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in South San Francisco, United States and has 44 employees. The company is worth $275.5M. Revenue was $3.48M in fiscal 2025, down 67.4% from the year before. It reported a net loss of $242.03M. The share price is 38.0% below its 52-week high of $37.83. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $17.73M. In that quarter, 1 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -82.8% over 5Y.
today you would have $223.24▼ -77.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $22.60 | $14.35 | $9.40 | $8.73 | $96.60 | |
| P/S | 4.4x | 74.7x | 4.4x | — | 1.4x | — |
| P/B | 0.8x | — | — | 0.8x | 0.2x | 2.1x |
| EPS | -$32.37 | -$21.67 | -$21.33 | -$15.56 | -$33.15 | |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CLPTClearPoint Neuro, Inc. | $9.07 | — | 25.7x | 0.00% | -226.52% | $276.67M |
| TMCITreace Medical Concepts Inc | $4.28 | — | 4.1x | 0.00% | -71.99% | $278.35M |
| FULCFulcrum Therapeutics, Inc. | $3.68 | — | 0.9x | 0.00% | -32.38% | $281.09M |
| MOBIMobia Medical, Inc. | $8.09 |
| Profit margin |
| -596.56% |
| -6960.77% |
| -596.56% |
| — |
| -288.03% |
| — |
| ROE | -49.82% | — | — | -113.46% | -47.37% | -49.82% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 1.6x |
| 0.00% |
| — |
| $269.32M |
| ANIKAnika Therapeutics, Inc. | $21.09 | — | 2.1x | 0.00% | -2.19% | $282.25M |
| BNTCBenitec Biopharma Inc. | $8.11 | — | 1.6x | 0.00% | -33.21% | $282.9M |